{"task_id": "52631bf471982797", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 73/464)", "text": "th ARB), angioe\ndema, hyperkalemia\n58\nHypertension\n\n--- Page 80 ---\nTREATMENT ISSUES (CONT\u2019D)\nb BLOCKERS\n\u0002\nINDICATIONS\nresting tachycardia, HF, migraine,\nglaucoma, CAD/post MI\n\u0002\nCONTRAINDICATIONS\nasthma, severe PVD, Ray\nnaud\u2019s phenomenon, depression, bradycardia, sec\nond or third degree heart block and hypoglyce\nmia prone diabetics\n\u0002\nADVERSE EFFECTS\ndepression, # exercise tolerance,\nbradycardia, hypotension\nCALCIUM CHANNEL BLOCKERS\n\u0002\nDIHYDROPYRIDINE\n(potent\nvasodilators)\nnifedi\npine, nicardipine, amlodipine, felodipine\n\u0002\nNON-DIHYDROPYRIDINE (heart rate control)\nverapa\nmil (cardiac depressant activity), diltiazem (some\ncardiac depressant, some vasodilator)\n\u0002\nINDICATIONS\nangina pectoris, recurrent SVT (ver\napamil), Raynaud\u2019s phenomenon (dihydropyri\ndine), migraine, heart failure due to diastolic dys\nfunction, esophageal spasm\n\u0002\nCONTRAINDICATIONS\nsecond or third degree heart\nblock (non dihydropyridine), HF with moderate to\nmarked systolic dysfunction\n\u0002\nADVERSE EFFECTS\nnifedipine (dizziness, headache,\nflushing, and peripheral edema), verapamil (# car\ndiac contractility, conduction, and constipation),\ndiltiazem (both side effects but a lot less severe)\nTREATMENT ISSUES (CONT\u2019D)\nDIURETICS\n\u0002\nINDICATIONS\nmost patients, particularly those of\nAfrican descent, edema, HF, elderly\n\u0002\nCONTRAINDICATIONS\nallergy\n\u0002\nADVERSE EFFECTS\n# K, hyperuricemia, \" choles\nterol, \" glucose, \" insulin resistance, impotence\nBLOOD PRESSURE TREATMENT TRIGGERS AND\nTARGETS\nBlood\npressure\n(mmHg)\nWhen to start therapy?\nNo macrovascular target organ\ndamage\nMacrovascular target organ\ndamage or cardiovascular risk\nfactors\n160/100\n140/90\nWhat should the targets be?\nDiabetes, chronic kidney disease\nAll others\n<130/80\n<140/90\nCHEP Guidelines 2009\nhttp://www.hypertension.ca\nOVERALL APPROACH TO CHOICE OF THERAPY\nCondition\nDrug of Choice\nHTN without other\nindications\nA/B/C/D ! AC/AD/BC/BD ! ABC/ACD/BCD/ABD ! ABCD\nAvoid B as first line if age >60\nACEi may be less effective in blacks\nIsolated systolic hypertension\nARB/C1/D ! ARB plus either C1 or D ! ARB plus C1 plus D\nAvoid B\nAngina\nACEi/B ! ACEi plus B ! add C1\nPrior myocardial infarction\nAB ! ABC\nHeart failure\nAB ! ABD (including spironolactone) ! ACEi/ARB/B/D. Avoid hydralazine\nand minoxidil if LVH\nPrior cerebrovascular disease\nAD ! add other agents\nPeripheral vascular disease\nA/B/C/D plus ASA.\nAvoid B if severe PVD\nDiabetes without\nnephropathy\nA/C1/D ! AC1/AD ! add B or C2\nDiabetes with nephropathy\nA ! AC/AB/AD\nCKD \u0007 proteinuria\nA ! AD ! add other agents\nAsthma\nA/C/D. Avoid B\nBPH\na blockers\nPerioperative\nB (if moderate to high risk)\nMigraine\nB\nThyrotoxicosis\nB\nEssential tremor\nB\nPostural hypotension\nAvoid vasodilators and diuretics\nRaynaud\u2019s\nC (dihydropyridine)\nGout\nD\nOsteoporosis\nD\nHypertension\n59", "text_length": 2752, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 73/464)", "type": "chunk", "chunk_index": 72, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.336364", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.337068", "status": "complete", "chunks_added": 2}